Stéphane Angers

The paper develops RIZLiver to infer zonal identity from gene expression in liver disease, showing loss of zone-3 identity in MASLD and therapeutic potential through zonal restoration.

This study identifies TRIM9 as a sex-specific regulator of the Aβ42/PrPC/mGluR5 complex in male Alzheimer's mice, linking it to pathological signaling and autophagy.

This study identifies induced-proximity drugs that target β-catenin in colorectal cancer by recruiting Casein kinase I, leading to its degradation and inhibiting tumor growth.

This study shows that an FZD4/LRP5 agonist improves pericyte coverage and vascular integrity by enhancing PDGFB signaling in a mouse model of pericyte deficiency.

This study shows that liver-specific loss of ARGLU1 in mice prevents diet-induced obesity without affecting food intake, locomotion, or energy expenditure, due to reduced lipid absorption and altered bile acid metabolism.

This study identifies ORB2 as a regulator of maternal mRNAs during the Drosophila MZT, showing its ZZ domain mediates repression through interactions with post-transcriptional regulators.

This study shows that C1QA maintains blood-retina barrier function and limits cystoid edema by supporting beta-catenin-dependent signaling in a mouse model of retinal disease.

This study uses CRISPR/Cas9 screening to identify genes regulating α-synuclein fibril uptake via heparan sulfate proteoglycans, revealing SLC39A9 and C3orf58 as key modulators.

This study identifies SRRM1 as a splicing regulator that promotes oncogenic NUMB isoforms and other cancer-related splicing events, leading to increased tumorigenic properties in multiple cancer cell lines.

This study identifies DNA-PK as a synthetic lethal target in TP53-deficient SHH medulloblastoma, showing that inhibiting DNA-PK enhances radiosensitivity and improves survival in preclinical models.

This study identifies EP300 as a regulator of the Injury-Response state in Glioblastoma Stem Cells through a CRISPR-Cas9 screen, showing its role in maintaining IR state features and tumor aggressiveness.

This study maps the acetyl lysine machinery interactions and identifies MAPKAPK2 as a factor contributing to resistance to BET bromodomain inhibitors in melanoma.

The paper identifies Perlecan as a factor that influences muscle stem cell re-quiescence, showing its age-related changes and therapeutic potential.

The paper identifies Usp5 as a key interactor of Brat that facilitates pre-complex assembly for mRNA degradation during differentiation in Drosophila.

This paper identifies PRMT5 as a regulator of HTT mRNA splicing and alternative polyadenylation, showing that its inhibition reduces full-length HTT protein levels by promoting premature termination and cleavage.

This study identifies SR-4835 as a CDK12 inhibitor that promotes cyclin K degradation via the proteasome by recruiting the CDK12-cyclin K complex to the CUL4-RBX1-DDB1 ubiquitin ligase complex.

The paper uses mtDNA-damaging agents and CRISPR screening to identify genes essential for mtDNA damage response, finding WRNIP1 essential for mtDNA repair and mitochondrial turnover.

This study uses single-molecule imaging to analyze Dvl2 dynamics and oligomerization during Wnt pathway activation, showing increased oligomerization and dwell time upon Wnt3a stimulation.

The paper shows that precise degradation of post-transcriptional repressors during the Drosophila MZT is essential for orderly transition to zygotic gene control.

This study identifies RIN/G3BP-bound mRNAs in Drosophila and shows they are short, stable, and highly translated, suggesting RIN stabilizes and enhances their translation.

The paper shows that PKM inhibits translation of 7% of the transcriptome under high glucose and pyruvate conditions by stalling ribosome elongation, linking glycolysis to protein synthesis and cell cycle regulation.

The paper presents a high-throughput CRISPR-Cas9 screening method for identifying CD47 modulators, identifying QPCTL as a key enzyme involved in its pyroglutamyl modification.

drugZ identifies chemogenetic interactions from CRISPR screens, finding more homologous recombination repair pathway genes and confirming KEAP1 loss as a resistance factor for ERK inhibitors.

The paper identifies a WNT7B-FZD5 signaling circuit as a therapeutic target in pancreatic cancer using CRISPR screening and validates it with antibodies.